Skip to main content

6 Result(s)

within Stefania Bartolini Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    Machine learning in neuro-oncology: toward novel development fields

    Artificial Intelligence (AI) involves several and different techniques able to elaborate a large amount of data responding to a specific planned outcome. There are several possible applications of this technol...

    Vincenzo Di Nunno, Mario Fordellone, Giuseppe Minniti… in Journal of Neuro-Oncology (2022)

  2. No Access

    Article

    Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?

    The clinical management of glioblastoma (GBM) is still bereft of treatments able to significantly improve the poor prognosis of the disease. Despite the extreme clinical need for novel therapeutic drugs, only ...

    Lidia Gatto, Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni… in Drugs (2022)

  3. No Access

    Article

    Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis

    The canonical isocitrate dehydrogenase 1 R132 mutation (IDH1 R132) is the most frequent mutation among IDH-mutated gliomas. Non-canonical IDH1 mutations or IDH2 mutations are unusual and their clinical and biolog...

    Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni, Lidia Gatto… in Advances in Therapy (2022)

  4. No Access

    Article

    Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?

    Breast cancer (BC) is the second most common tumour spreading to the central nervous system (CNS). The prognosis of patients with CNS metastases depends on several parameters including the molecular assessment...

    Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni… in Clinical Drug Investigation (2021)

  5. No Access

    Article

    Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?

    Standard glioblastoma therapy is long-lasting. Among second-line therapy, choices could be bevacizumab and nitrosoureas depending on National Agencies approval. There is no consensus on 3rd line therapy or cli...

    Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo… in Journal of Neuro-Oncology (2018)

  6. No Access

    Article

    Post progression survival in glioblastoma: where are we?

    The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM pa...

    Enrico Franceschi, Mario Ermani, Stefania Bartolini… in Journal of Neuro-Oncology (2015)